ERBB2 and breast carcinoma: Our study showed that a total of eleven DSI quantitative parameters, including DTI_RD, DTI_MD, DKI_AK, MAP_NG, MAP_NGAx, MAP_NGRad, MAP_MSD, MAP_QIV, MAP_RTOP, MAP_RTAP, and NODDI_ICVF, significantly differed between HER2-negative and HER2-positive breast cancers.